AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03189342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single task training
Description: The participants in single task training received 30 minutes single task balance and gait exercises, 3 times a week for 4 weeks. The program included static and dynamic balance exercises. Static balance exercises involved body stability (e.g., standing legs open and closed, standing with eyes closed, tandem standing, standing on foam surface and one leg standing, standing while throwing and catching a ball ), forward and backward weight shifting and keeping standing position while being disturbed by external perturbation. Dynamic balance exercises included tandem walking, walking to different direction (backward, side to side), transfer activities (from 1 chair to another) and sit to stand 5 times
Study NCT03189342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dual task training
Description: The participants practiced 30 minutes balance and gait exercises while simultaneously performing cognitive tasks. The program included static and dynamic balance exercises. Static balance exercises involved body stability, forward and backward weight shifting and keeping standing position while being disturbed by external perturbation. Dynamic balance exercises included tandem walking, walking to different direction, transfer activities and sit to stand 5 times. The participants practiced cognitive tasks while simultaneously performing balance and gait exercises. The cognitive tasks included visual attention, auditory attention, planning, verbal fluency, simple mental math and maze activities. At each week, participants performed different type of activities which were designed to foster the executive functions: (1) Visual and auditory attention, (2) Planning and verbal fluency, (3) Simple math problems (4) Visual and auditory attention, planning, verbal fluency, math problems
Study NCT03189342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise-cognitive activity combined training
Description: The participants first practiced 30 min of cognitive activities then performed 30 min of balance and gait exercises after 5 min of resting.The program included static and dynamic balance exercises. Static balance exercises involved body stability, forward and backward weight shifting and keeping standing position while being disturbed by external perturbation. Dynamic balance exercises included tandem walking, walking to different direction, transfer activities and sit to stand 5 times. The cognitive tasks included visual attention, auditory attention, planning, verbal fluency, simple mental math and maze activities. At each week, participants performed different type of activities which were designed to foster the executive functions: (1) Visual and auditory attention, (2) Planning and verbal fluency, (3) Simple math problems (4) Visual and auditory attention, planning, verbal fluency, math problems.
Study NCT02349152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Subjects in the experimental group will receive remifentanil infusion 0.1-0.4ug/kg/minute before induction of anesthesia and continued until skin closure. During cardiopulmonary bypass, remifentanil infusion will be increased to 0.5-1 ug/kg/min as hemodynamically tolerated.
Study NCT02349152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Subjects in the control group will initially receive intermittent boluses of Fentanyl in the range of 50-250 ug. Additional fentanyl can be given titrated to hemodynamic parameters throughout surgery.
Study NCT03272503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimozide 2mg/day (current) or 4 mg/day (study initiation)
Description: Pimozide 2mg tablets will be taken once daily.
Study NCT03860766 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Photobiomodulation
Description: An LED blanket with 267 infrared lamps with predetermined doses will be used, given a wavelength of 940nm, for 5 weeks, it will be applied by all extension of the quadriceps and hamstrings bilaterally, just before the force training protocol for the groups intervention or simulation for the sham group. Photochemical or photophysical effects are expected from its application.
Study NCT00159107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acamprosate
Description: Acamprosate
Study NCT00159107 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative behavior therapy
Description: Integrative behavior therapy
Study NCT00159107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT00826150 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BC-819
Description: Cohort #1: 60 mg IP weekly for 3 weeks, one week rest, then repeat for 2 more courses / 60 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.~Cohort #2: 120 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.~Cohort #3: 240 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.
Study NCT03603561 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cTBS
Description: In the cTBS arm, the patients will receive 5 daily session cTBS (5 times uninterrupted train of 900 pulses) separated by a 15 min interval. Patients will be treated with in total 20 cTBS sessions over the right dorsolateral prefrontal cortex, spread over 4 days. A stimulation intensity of 100 % of the resting motor threshold (rMT) of the right abductor pollicis brevis muscle will be used.
Study NCT03603561 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham cTBS
Description: The sham coil has been specifically developed to mimic the real one but is not associated with a stimulus sensation compared to the coil delivering real stimulation cTBS.
Study NCT02333422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NIRS Neurofeedback
Description: The sensor will be placed on 4 specific regions defined by the International 10/20 System for Electrode Placement. F7, Fp1, Fp2 and F8. Each region will be initially trained for 4 minutes, with the eyes open, gradually increasing training time throughout the sessions to a maximum of 10 minutes. Training will amount to 24 sessions, occurring 2 times per week over a period of 3 moths. The procedure will be interrupted at any time, should the subject demonstrate the desire to stop.
Study NCT03717649 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional 2-stage venous cannula
Description: venous cannula
Study NCT03717649 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional 3-stage venous cannula
Description: venous cannula
Study NCT03717649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fenestrated 3-stage venous cannula
Description: venous cannula
Study NCT02393235 — intervention group
Intervention type: OTHER
Intervention: doppler ultrasonography
Description: Ovarian, uterine and spiral artery pulsatility index and resistance index will measure
Study NCT03272503 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Identical matching placebo lactose tablets
Study NCT03030313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reassure Non-Contact Respiration Monitor
Description: Reassure Respiration Monitor uses very low power radio waves to detect respiratory movements of a person while asleep in bed - without physical contact with the individual. Algorithms analyze the respiratory movement signals and extract information about respiration rate and variability. This data is uploaded to a secure cloud infrastructure for storage.
Study NCT01218347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 20 mg once daily for 21 days
Study NCT03903718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: 75 mg capsules orally twice a day from Day 2 to Day 7
Study NCT03903718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: 75 mg capsules orally twice a day from Day 2 to Day 7
Study NCT03903718 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI8852
Description: MEDI8852 is a human IgG1 kappa monoclonal antibody administered as a single IV infusion at either dose 1 or dose 2 on Day 2.
Study NCT03903718 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Placebo is salt-water solution containing no active ingredients and administered as a single IV infusion on Day 2.
Study NCT01594827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Vancomycin
Description: On Days 1-28, subjects will receive nebulized Vancomycin. This will be supplied as a 250 mg solution to be nebulized two times a day for 28 days in 5cc sterile water. Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
Study NCT01594827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (Sterile Water)
Description: On Days 1-28, subjects will receive 5cc of a nebulized Placebo (Sterile water) twice a day. This is a taste (quinine 0.1mg/mL) matched nebulized placebo (sterile water). Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
Study NCT01594827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: Oral Rifampin by mouth for 28 days~1. >45 kg: 600 mg by mouth daily~2. 35-45 kg : 450 mg by mouth daily~3. 25-34.9 kg: 300 mg by mouth daily
Study NCT01594827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Oral Rifampin by mouth for 28 days~1. >45 kg: 600 mg by mouth daily~2. 35-45 kg : 450 mg by mouth daily~3. 25-34.9 kg: 300 mg by mouth daily
Study NCT01594827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimethoprim/Sulfamethoxazole (TMP/SMX)
Description: Oral trimethoprim/sulfamethoxazole (DS-160/800)~1. >45 kg: two DS tablets twice a day by mouth (320/1600)~2. 25-45 kg: one DS tablet twice a day by mouth (160/800)
Study NCT01594827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim/Sulfamethoxazole (TMP/SMX)
Description: Oral trimethoprim/sulfamethoxazole (DS-160/800)~1. >45 kg: two DS tablets twice a day by mouth (320/1600)~2. 25-45 kg: one DS tablet twice a day by mouth (160/800)
Study NCT01594827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: If sulfa intolerant or TMP/SMX Resistant, use instead oral doxycycline~1. >45 kg: 100 mg by mouth twice a day~2. 35-45 kg : 75 mg by mouth twice a day iii. 25-34.9 kg: 50 mg by mouth twice a day
Study NCT01594827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: If sulfa intolerant or TMP/SMX Resistant, use instead oral doxycycline~1. >45 kg: 100 mg by mouth twice a day~2. 35-45 kg : 75 mg by mouth twice a day iii. 25-34.9 kg: 50 mg by mouth twice a day
Study NCT01594827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin Intranasal Creme
Description: Mupirocin 2% intranasal creme: half of single use tube applied into each nostril twice a day for 5 days.
Study NCT01594827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin Intranasal Creme
Description: Mupirocin 2% intranasal creme: half of single use tube applied into each nostril twice a day for 5 days.
Study NCT01594827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4% chlorhexidine gluconate liquid skin cleanser
Description: Hibiclens 15cc liquid skin cleanser packets (4% chlorhexidine gluconate): use three packets once weekly for four weeks in the shower from the neck to toes, with attention on the axilla, groin, and buttocks.
Study NCT01594827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine gluconate liquid skin cleanser
Description: Hibiclens 15cc liquid skin cleanser packets (4% chlorhexidine gluconate): use three packets once weekly for four weeks in the shower from the neck to toes, with attention on the axilla, groin, and buttocks.
Study NCT01736189 — intervention group
Intervention type: DRUG
Intervention: Adalimumab
Description: Pre-filled syringe, administered by subcutaneous injection
Study NCT03608059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG/PTCy
Description: low dose Antithymocyte Globulin plus low dose post-transplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation
Study NCT03608059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard ATG
Description: in vivo T cell depletion (TCD) with anti-thymocyte globulin (ATG) as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation
Study NCT03608059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard PTCy
Description: post-transplant cyclophosphamide (PTCy) as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell
Study NCT04480606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home exercise program
Description: 47 volunteers over 65 years old who are at home during the social isolation process due to the coronavirus outbreak will be included in home exercise group. A video exercise protocol was created and each exercise session was planned as daily 30 minutes for 6 weeks. Individuals will ask to do their exercises. It was planned to start the protocol with warm-up exercises and finish with cooling exercises. The exercise protocol was additionally determined as a combination of aerobic, balance and strengthening exercises. The exercise program consists of 3 levels and individuals will be provided to start at a level appropriate to their level of physical activity.
Study NCT00240214 — intervention group
Intervention type: DRUG
Intervention: sirolimus
Description: Tablet, dosage is determined by trough level
Study NCT03258736 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: inguinal hernia surgery
Description: repair of inguinal hernia
Study NCT01502046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)
Description: Sativex 2.7 mg delta-9-tetrahydrocannabinol/2.5 mg cannabidiol Oromucosal Spray. One spray per day, up to a maximum of 12 sprays per day.
Study NCT01502046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, One spray per day, up to a maximum of 12 sprays per day.
Study NCT01947569 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Biological
Study NCT01947569 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Biological
Study NCT01947569 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological
Study NCT01517997 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paclitaxel coated balloon angioplasty.
Description: Infrapopliteal angioplasty using a paclitaxel coated balloon.
Study NCT01517997 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infrapopliteal Primary Drug Eluting Stenting
Description: Infrapopliteal primary stenting using drug-eluting stent(s)
Study NCT02693704 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aids
Description: The only intervention consists in applying a specific processing on some recorded speech signals, and comparing the performance obtained with such processed samples with ones that have not been processed. The applied processing is a binaural spatialization method that consists in filtering an original audio signal to get a left and right versions (for the two ears). The binaural rendering gives the impression that the speech signal (and thus the speaker) is located in a desired position in the environment.
Study NCT00399841 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Precision for Spinal Cord Stimulation
Description: During Trial Implant Period, stimulation from single lead initially turned on at the T7 or T8 level, then crossover. At time of permanent implant, subject chooses which level they want the stimulator turned on.
Study NCT04685746 — intervention group
Intervention type: BEHAVIORAL
Intervention: Balanced Growth Protocol
Description: Assessment of the Balanced Growth Protocol, consisting of audiovestibular testing, motor and cognitive tasks
Study NCT02815020 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Boot Camp Translation - community-participatory process
Description: Series of meetings and conference calls with expert presentation on patient self-management support, facilitated discussion, and creation of product to bring to community to improve patient self-management support
Study NCT03022955 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dark chocolate bar
Description: Dark chocolate bar (70% cocoa solids (\~500kcal, \~50% fat)), 100g / day for 3 days to assess postprandial brain activity and colonic transit by FDG-PET.
Study NCT03022955 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dark chocolate mousse
Description: Dark chocolate mousse (150g, \~500kcal, \~50% fat) to assess gastric emptying and oro-caecal transit time by scintigraphy.
Study NCT03022955 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: White chocolate bar
Description: White chocolate bar (0% cocoa solids (\~500kcal, 50% fat)), 100g / day for 3 days to assess postprandial brain activity and colonic transit by FDG-PET.
Study NCT03022955 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: White chocolate mousse
Description: White chocolate mousse (150g, \~500kcal, \~50% fat) to assess gastric emptying and oro-caecal transit time by scintigraphy.
Study NCT01487187 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Milking the umbilical cord at birth
Description: Infants in the cord-milked group will be placed at or below the level of the placenta, and about 20 cm of the umbilical cord (or the length of cord that is accessible if less than 20 cm) will be vigorously milked towards the umbilicus three times before clamping the cord
Study NCT01487187 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: immediate umbilical cord clamping
Description: immediate cord clamping without milking as per standard practice
Study NCT01271504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Phase Ib: Cohort 1; 200 mg E7050 + 400 mg Sorafenib Cohort 2; 300 mg E7050 + 400 mg Sorafenib Cohort 3; 400 mg E7050 + Sorafenib
Study NCT01271504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: E7050 given orally at 200, 300 or 400 mg once daily.~Sorafenib given orally, 400 mg twice daily.
Study NCT03158909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eyemask and earplugs
Description: Eyemask and earplugs for use during the night, to improve sleep.
Study NCT03158909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orientation about space and time
Description: Information and orientation about space and time, given every night.
Study NCT03158909 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orientation about space and time
Description: Information and orientation about space and time, given every night.
Study NCT05281497 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health platform
Description: Each participant was provided with a wearable device (a Heart Rate Smart Wristband, GSH405-B6, Golden Smart Home Technology Corporation). Each participant downloaded an app (WowGoHealth app) to connect with the health management platform (GSH AI health platform). Participants' exercise-related data, including number of steps walked, distance, consumed calories, and heart rate, were collected by the wearable devices. All participants were taught to record a dietary diary (taking photos of meals) using a smartphone application. All collected information was uploaded to the health management platform. For the intervention group, we encouraged exercise including an 18-minutes calisthenics made by the Health Promotion Administration, Ministry of Health and Welfare (https://www.youtube.com/watch?v=r3xJW-b2tZY).
Study NCT05281497 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health platform
Description: Each participant was provided with a wearable device (a Heart Rate Smart Wristband, GSH405-B6, Golden Smart Home Technology Corporation). Each participant downloaded an app (WowGoHealth app) to connect with the health management platform (GSH AI health platform). Participants' exercise-related data, including number of steps walked, distance, consumed calories, and heart rate, were collected by the wearable devices. All participants were taught to record a dietary diary (taking photos of meals) using a smartphone application. All collected information was uploaded to the health management platform. For the intervention group, we encouraged exercise including an 18-minutes calisthenics made by the Health Promotion Administration, Ministry of Health and Welfare (https://www.youtube.com/watch?v=r3xJW-b2tZY).
Study NCT05281497 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social media
Description: We built a LINE group to inspire the intervention group.
Study NCT05281497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: exercise including walk and an 18-minutes calisthenics
Study NCT04541368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS1 Targeted CAR T-cells
Description: Each subject receive CS1 Targeted CAR T-cells by intravenous infusion
Study NCT00777062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIVITROL (Naltrexone extended-release injectable suspension)
Description: VIVITROL (Naltrexone extended-release injectable suspension), 380 mg injection at the start of weeks 2 and 6.
Study NCT00777062 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injection at the start of weeks 2 and 6.
Study NCT02946671 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mogamulizumab
Description: Mogamulizumab (0.1, 0.3 or 1.0 mg/kg) is administered.